Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2023-11-21 Investor Presentation
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Shareholder Town Hall slides 17 pages 10.9MB
Investor Presentation Classification · 100% confidence The document is titled as an 'Investor Presentation' dated 22 November 2023 and contains detailed information about the company's business, market opportunity, drug development programs, competitive advantages, and regulatory pathways. It includes forward-looking statements, market data, clinical trial phases, and strategic plans. There is no indication that this is a regulatory filing, earnings release, or annual report. The content is consistent with a presentation aimed at investors to inform them about the company's strategy, pipeline, and market potential. Therefore, the document fits the category of an Investor Presentation (IP). The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary, confirming it is the presentation itself.
2023-11-21 English
Shareholder Webinar - 12pm AEDT on Wed 22 Nov 2023 2 pages 175.6KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 20 November 2023 inviting shareholders to a webinar (Shareholder Town Hall Webinar) scheduled for 22 November 2023. It provides details on how shareholders can participate and submit questions. The document mentions that presentation slides will be lodged on the ASX immediately prior to the webinar but does not contain any financial data, results, or detailed report content itself. The document is short (2623 characters) and serves as an announcement of an upcoming event rather than a report or transcript. Therefore, it fits best under the category of Investor Presentation (IP) as it is a detailed presentation for investors focusing on company updates and strategy, even though the actual slides are to be provided later. It is not a Call Transcript (CT) because the webinar has not yet occurred, nor is it a Report Publication Announcement (RPA) because it is not announcing a report release. Hence, the classification is Investor Presentation (IP) with high confidence.
2023-11-19 English
Clarification of claim against significant IRX shareholder 2 pages 177.2KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated 9 November 2023 regarding a legal claim against a significant shareholder of InhaleRx Ltd. It discusses the involvement of the shareholder and related parties, the company's position, and the board's monitoring plans. There are no financial statements, no report attachments, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. The content focuses on a legal matter update related to a shareholder and company operations. This fits the category of Legal Proceedings Report (LTR). The document length is 3392 characters, which is short but contains substantive information about a legal claim, not just a notice or certification. Therefore, the best classification is LTR with high confidence.
2023-11-08 English
Sep23 Quarterly Activities Report 4 pages 285.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 October 2023, titled 'QUARTERLY ACTIVITIES, CASHFLOW REPORT and OPERATIONS UPDATE' for the quarter ended 30 September 2023. It contains detailed operational highlights, cash flow figures, clinical trial updates, regulatory progress, capital requirements, and payments to directors and related parties. The document includes substantive financial data such as cash reserves, net cash used in operating activities, R&D expenditure, and other operating costs. It also provides a comprehensive update on clinical development and regulatory activities. The length of the document (8811 characters) and the detailed financial and operational content indicate it is a comprehensive quarterly report rather than a brief announcement or a simple regulatory filing. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement of a report or a certification, nor is it a full annual report or earnings release. Hence, the correct classification is IR with high confidence. Q1 2023
2023-10-30 English
Sep23 Appendix 4C 5 pages 304.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 30 September 2023. It includes actual financial data such as cash flows, payments to related parties, financing facilities, and estimated cash available for future operations. The document is a quarterly cash flow report, which is a type of interim or quarterly financial report. It is not an announcement or a certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-30 English
IRX presents at AusBioInvest 2023 15 pages 9.6MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 30 October 2023, titled 'IRX PRESENTS AT AUSBIOINVEST 2023'. It includes a detailed presentation with slides about InhaleRx Ltd's business, market opportunity, drug development plans, and investment opportunity. The content is structured as a presentation given at a conference, with forward-looking statements, market data, and company strategy. There are no financial statements or detailed financial results, nor is this a regulatory filing or certification. The document explicitly states it is an 'Investor Presentation' and includes slides and detailed information aimed at investors. Therefore, this document fits the category of an Investor Presentation (IP). The document length is substantial (15,000 characters), and it contains the full presentation, not just an announcement of a report publication or a brief summary. Confidence is high given the explicit labeling and content type.
2023-10-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.